IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Fiduciary Trust Co

Fiduciary Trust Co decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.8% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 6,146 shares of the medical research company’s stock after selling 51 shares during the period. Fiduciary Trust Co’s holdings in IQVIA were worth $1,456,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. PGGM Investments grew its position in IQVIA by 55.8% in the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after acquiring an additional 4,326 shares during the period. Simplify Asset Management Inc. grew its holdings in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the period. Raymond James & Associates raised its holdings in IQVIA by 0.7% in the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after buying an additional 5,417 shares during the period. Versor Investments LP acquired a new position in IQVIA in the third quarter valued at about $1,328,000. Finally, Gradient Investments LLC boosted its stake in IQVIA by 15.6% during the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after buying an additional 6,134 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 0.2 %

IQVIA stock opened at $200.96 on Friday. The stock has a market cap of $36.47 billion, a PE ratio of 26.37, a P/E/G ratio of 2.07 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock’s fifty day moving average is $218.67 and its two-hundred day moving average is $226.20. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

Analysts Set New Price Targets

Several equities analysts have recently commented on IQV shares. Redburn Atlantic began coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. Robert W. Baird decreased their price target on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research note on Friday, November 1st. Barclays dropped their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. Finally, The Goldman Sachs Group lowered their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.